NCT00453570View on ClinicalTrials.gov

Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months

PHASE3CompletedINTERVENTIONAL
Enrollment

792

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2009

Conditions
DiphtheriaTetanusHaemophilus Influenzae Type bPertussisPoliomyelitis
Interventions
BIOLOGICAL

Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib

0.5 mL, IM

BIOLOGICAL

Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib

0.5 mL, IM

BIOLOGICAL

Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed

0.5 mL, IM

Trial Locations (1)

530022

Nanning

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT00453570 - Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months | Biotech Hunter | Biotech Hunter